Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan - Concepedia

Concepedia

Publication | Open Access

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

DOI Full Paper Access

79

Citations

29

References

2019

Year

Masahiro Kobayashi, Masatoshi Kudo, Namiki Izumi, Shuichi Kaneko, Mie Azuma, Ronda Copher, Genevieve Meier, Janice Pan, Mika Ishii, Shunya Ikeda

Journal of Gastroenterology

Abstract

Lenvatinib was cost-effective compared with sorafenib for the first-line treatment of uHCC in Japan.

References

	Year	Citations

Page 1